SCHEMBL16907553

SCHEMBL16907553

Nc1cc(CN2CCNCC2)cc(C(F)(F)F)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 4/20 0.59
CYP3A4 P08684 3/20 0.59
TSHR P16473 2/20 0.54
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
TP53 P04637 1/20 0.51
CYP2C19 P33261 2/20 0.46
CYP2C9 P11712 1/20 0.46
ADRB1 P08588 1/20 0.45
SIGMAR1 Q99720 1/20 0.44
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
GAA P10253 1/20 0.43
CHRM3 P20309 2/20 0.42
CASP1 P29466 1/20 0.42
CASP5 P51878 1/20 0.42
USP2 O75604 1/20 0.42
CYP1A2 P05177 1/20 0.42
DDR1 Q08345 1/20 0.41
CHRM2 P08172 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19262510 0.89 CYP2D6 (0.72) CYP2D6CYP3A4TSHRMEN1KMT2A
SCHEMBL20676125 0.87 CYP2D6 (0.70) CYP2D6CYP3A4TSHRMEN1KMT2A
SCHEMBL545692 0.86 ALDH1A1 (0.58) CYP2D6CYP3A4TSHRMEN1KMT2A
SCHEMBL4935986 0.86 ALDH1A1 (0.54) CYP2D6CYP3A4TSHRMEN1KMT2A
SCHEMBL29967920 0.86 ALDH1A1 (0.58) CYP2D6CYP3A4TSHRMEN1KMT2A
SCHEMBL545978 0.84 ALDH1A1 (0.60) CYP2D6CYP3A4TSHRMEN1KMT2A
Hydrochloric Acid SCHEMBL30349712 0.84 ALDH1A1 (0.56) CYP2D6CYP3A4TSHRMEN1KMT2A
SCHEMBL19262611 0.83 CYP3A4 (0.61) CYP2D6CYP3A4TSHRMEN1KMT2A
SCHEMBL545422 0.82 ALDH1A1 (0.47) CYP2D6CYP3A4TSHRMEN1KMT2A
SCHEMBL545449 0.82 LMNA (0.53) CYP2D6CYP3A4TSHRCYP2C19KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2864289-B1 CYCLOPROPANECARBOXAMIDO-SUBSTITUTED AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS CB THERAPEUTICS INC (KY) 2018-04-11 EP disclosed
US-9359338-B2 Cyclopropanecarboxamido-substitute aromatic compounds as anti-tumor agents CROWN BIOSCIENCE INC. (TAIWAN) (TW) 2016-06-07 US disclosed
US-20150197511-A1 CYCLOPROPANECARBOXAMIDO-SUBSTITUTE AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS APOLLOMICS INC. 2015-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150197511-A1 CYCLOPROPANECARBOXAMIDO-SUBSTITUTE AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS BRAF, ARAF, RAF1 CYP2D6 3787/4885CYP3A4 3398/4885TSHR 3443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.